Skip to main content
SpringerLink
Log in

Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The tamoxifen-resistant (TAM-R) MCF-7 breast cancer cell line has been used as a model to identify the signalling pathways that enable resistant cancer cells to grow independently of steroid hormones. In TAM-R cells, peptide growth factor signalling pathways appear to be important in modified cell behaviour, growth and survival. The PI3 kinase signalling components Akt1 and Akt2 are expressed at similar levels by both parental wild-type MCF-7 and TAM-R cells, but Akt1 phosphorylation is significantly increased in TAM-R cells grown under basal conditions. High levels of basal Akt, GSK3α/β and p70S6 kinase phosphorylation are all inhibited by the PI3 kinase inhibitor, LY 294002. The ligands for the EGFR/erbB1 receptor, EGF (epidermal growth factor) and TGFα(transforming growth factor-α) demonstrate an increased ability to activate Akt in TAM-R compared with parental MCF-7 cells and it is proposed that the preferred autocrine or paracrine activation of Akt occurs via the erbB heterodimer EGFR/erbB2 in TAM-R cells. Akt phosphorylation is reduced by gefitinib (“Iressa”/ZD1839). The results suggest that the PI3 kinase pathway plays a role in proliferation of TAM-R cells and is important in the increased EGF induced membrane ruffling detected in the resistant cells. Increased Akt1 activation may contribute to the aggressive phenotype of tamoxifen resistant ER (oestrogen receptor) positive breast cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1023–1044, 2003

    Google Scholar 

  2. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM: Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8: 175–182, 2001

    Google Scholar 

  3. Zinda MJ, Johnson MA, Paul JD, Horn C, Konicek BW, Lu ZH, Sandusky G, Thomas JE, Neubauer BL, Lai MT, Graff JR: AKT-1,-2, and-3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res 7: 2475–2479, 2001

    Google Scholar 

  4. Hill MM, Hemmings BA: Inhibition of protein kinase B/ Akt. Implications for cancer therapy. Pharmacol Ther 93: 243–251, 2002

    Google Scholar 

  5. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261–269, 1997

    Google Scholar 

  6. Scheid MP, Woodgett JR: Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 546: 108–112, 2003

    Google Scholar 

  7. Scheid MP, Marignani PA, Woodgett JR: Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 22: 6247–6260, 2002

    Google Scholar 

  8. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95: 5246–5250, 1998

    Google Scholar 

  9. Kandel ES, Hay N: The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253: 210–229, 1999

    Google Scholar 

  10. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153–1160, 2002

    Google Scholar 

  11. Staal SP: Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: ampli cation of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 84: 5034–5037, 1987

    Google Scholar 

  12. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is ampli ed in human ovarian carcinomas. Proc Natl Acad Sci USA 89: 9267–9271, 1992

    Google Scholar 

  13. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, et al: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64: 280–285, 1995

    Google Scholar 

  14. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 93: 3636–3641, 1996

    Google Scholar 

  15. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, Roth RA: Up-regulation of Akt3 in estrogen receptor-de cient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274: 21528–21532, 1999

    Google Scholar 

  16. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ: AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159: 431–437, 2001

    Google Scholar 

  17. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ: Phosphatidylino-sitol-3-OH Kinase (PI3K)/AKT2, activated in breast can-cer, regulates and is induced by estrogen receptor alpha (ERalpha)via interaction between ERalpha and PI3K. Cancer Res 61: 5985–5991, 2001

    Google Scholar 

  18. Stal O, Perez-Tenorio G, Akerberg L, Olsson B, Norden-skjold B, Skoog L, Rutqvist LE: Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5: R37–44, 2003

    Google Scholar 

  19. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV, Cheng JQ: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19: 2324–2330, 2000

    Google Scholar 

  20. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H: Phosphatidylinositol 3-kinase/ AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276: 9817–9824, 2001

    Google Scholar 

  21. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M: Integration of signal transduction inhibitors with endocrine therapy: an approach to over-coming hormone resistance in breast cancer. Clin Cancer Res 9: 524S–532S, 2003

    Google Scholar 

  22. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE, Stoica A: A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141: 4503–4511, 2000

    Google Scholar 

  23. Liu W, Li J, Roth RA: Heregulin regulation of Akt/protein kinase B in breast cancer cells. Biochem Biophys Res Commun 261: 897–903, 1999

    Google Scholar 

  24. Wells A: EGF receptor. Int J Biochem Cell Biol 31: 637–643, 1999

    Google Scholar 

  25. Newby JC, Johnston SR, Smith IE, Dowsett M: Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643–1651, 1997

    Google Scholar 

  26. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI: Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex). Endocrinology 142: 2776–2788, 2001

    Google Scholar 

  27. Vickers PJ, Dickson RB, Shoemaker R, Cowan KH: A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 2: 886–892, 1988

    Google Scholar 

  28. Long B, McKibben BM, Lynch M, van den Berg HW: Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br J Cancer 65: 865–869, 1992

    Google Scholar 

  29. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW: Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29: 117–125, 1994

    Google Scholar 

  30. Toi M, Osaki A, Yamada H, Toge T: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27: 977–980, 1991

    Google Scholar 

  31. Lacroix H, Iglehart JD, Skinner MA, Kraus MH: Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 4: 145–151, 1989

    Google Scholar 

  32. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI: The antiepidermal growth factor receptor agent ge tinib (ZD1839/Iressa)improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144: 5105–5117, 2003

    Google Scholar 

  33. Faridi J, Wang L, Endemann G, Roth RA: Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 9: 2933–2939, 2003

    Google Scholar 

  34. Pérez-Tenorio G, Stal O, Southeast Sweden Breast Cancer Group: Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86: 540–545, 2002

    Google Scholar 

  35. Hiscox S, Morgan L, Barrow D, Dutkowski C, Wakeling A, Nicholson RI: Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by ge tinib (“Iressa ”, ZD1839). Clin Exp Metastasis, 2004

  36. Kim D, Kim S, Koh H, Yoon SO, Chung AS, Cho KS, Chung J: Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 15: 1953–1962, 2001

    Google Scholar 

  37. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ: Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63: 196–206, 2003

    Google Scholar 

  38. Park BK, Zeng X, Glazer RI: Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res 61: 7647–7653, 2001

    Google Scholar 

  39. Rusch V, Mendelsohn J, Dmitrovsky E: The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 7: 133–141, 1996

    Google Scholar 

  40. Ram TG, Hosick HL, Ethier SP: Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells. J Cell Physiol 183: 301–313, 2000

    Google Scholar 

  41. Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R: Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 56: 3350–3358, 1996

    Google Scholar 

  42. deFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL: Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. I. Int J Cancer 87: 487–498, 2000

    Google Scholar 

  43. Martin LA, Farmer I, Johnston SR, Ali S, Marshall CJ, Dowsett M: Enhanced ERalpha ERBB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term oestrogen deprivation. J Biol Chem 278: 30458–30466, 2003

    Google Scholar 

  44. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JMW: Non-endocrine pathways and endocrine resistance: observations with anti-oestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10: 346–354s, 2004

    Google Scholar 

  45. Moasser MM, Basso A, Averbuch SD, Rosen N: The tyrosine kinase inhibitor ZD1839 (“Iressa ”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184–7188, 2001

    Google Scholar 

  46. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9: 2316–2326, 2003

    Google Scholar 

  47. Soltoff SP, Carraway KL III, Prigent SA, Gullick WG, Cantley LC: ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14: 3550–3558, 1994

    Google Scholar 

  48. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159–3167, 2000

    Google Scholar 

  49. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE: ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 18: 5042–5051, 1998

    Google Scholar 

  50. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC: HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275: 8027–8031, 2000

    Google Scholar 

  51. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132–4141, 2002

    Google Scholar 

  52. Shaw M, Cohen P: Role of protein kinase B and the MAP kinase cascade in mediating the EGF-dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells. FEBS Letters 461: 120–124, 1999

    Google Scholar 

  53. Clark AS, West K, Streicher S, Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707–717, 2002

    Google Scholar 

  54. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA: Role of translocation in the activation and function of protein kinase B. J Biol Chem 272: 31515–31524, 1997

    Google Scholar 

  55. Meier R, Alessi DR, Cron P, Andjelkovic M, Hemmings BA: Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase B beta. J Biol Chem 272: 30491–30497, 1997

    Google Scholar 

  56. Hill K, Welti S, Yu J, Murray JT, Yip SC, Condeelis JS, Segall JE, Backer JM: Specific requirement for the p85–p110 alpha phosphatidylinositol 3-kinase during epidermalgrowth factor-stimulated actin nucleation in breast cancer cells. J Biol Chem 275: 3741–3744, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, CF10 3XF, UK, Tel.:

    Nicola J. Jordan, Julia M.W. Gee, Alan E. Wakeling & Robert I. Nicholson

  2. AstraZeneca Pharmaceuticals, Mereside, Macclesfield, Cheshire, UK

    Denise Barrow

Authors
  1. Nicola J. Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia M.W. Gee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Denise Barrow
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alan E. Wakeling
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert I. Nicholson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jordan, N.J., Gee, J.M., Barrow, D. et al. Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells. Breast Cancer Res Treat 87, 167–180 (2004). https://doi.org/10.1023/B:BREA.0000041623.21338.47

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BREA.0000041623.21338.47

Search

Navigation